Navigation Links
Medivation Receives Corporate Achievement Award From Huntington's Disease Society of America
Date:10/16/2008

caused by the death of specific brain cells and is characterized by the gradual development of involuntary muscle movements, progressive deterioration of cognitive processes and memory (dementia), and severe behavioral disturbances.

About HDSA

HDSA is a national non-profit organization dedicated to improving the lives of people with Huntington's disease and their families. HDSA supports research to eradicate Huntington's disease and assists people and families affected by Huntington's disease.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding future clinical development plans, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progres
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
2. Medivation Announces Participation in Upcoming Conferences
3. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
4. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
5. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
7. Medivation Announces Senior Management Promotions
8. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
9. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
10. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
11. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine” or ... a fraudulent press release disseminated this morning by PR ... Immunovaccine. This press release states that Immunovaccine has entered ... The press release did not originate from Immunovaccine and ... the press release. Please note that all official ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Cytokinetics, ... forces on February 28 with patients and health care ... awareness for Rare Disease Day®. Rare Disease Day ... and calling attention to the special challenges faced by ... them. , “Cytokinetics is proud to stand alongside patients ...
(Date:2/26/2015)... 2015  23andMe, the leading personal genetics company, today ... Privacy Officer and Corporate Counsel. Black brings a strong ... well as health care regulations. As a member of ... for reviewing, updating and enhancing the company,s privacy and ... She joined the company January 5, 2015 and reports ...
Breaking Biology Technology:Immunovaccine Disclaims Hoax Press Release 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2
... 18 Jennifer Brownstein, Art Director at ... 2009 Rising Star by the Healthcare Businesswomen,s ... professionals in various sectors of the healthcare ... medical education, and market research. Nominated by ...
... /PRNewswire-Asia/ -- Obio Pharmaceutical Holdings Ltd,("Obio"/ "the ... the,international pharmaceutical arena. With a strong product ... international investors including Yangtze,Ventures Limited (New World ... Properties,Limited, Yu Hwa Chinese Products Group, YangtzeKiang ...
... a private,specialty pharmaceutical company, announced that the U.S. Food ... July 15, 2009 for,completion of its review of the ... Zogenix is seeking marketing approval,of Sumavel DosePro for the ... the acute treatment of cluster headache episodes. , ...
Cached Biology Technology:Jennifer Brownstein, of CONNEXION Healthcare, Honored as 'Rising Star' by Healthcare Businesswomen's Association 2Obio Pharmaceutical Announces Product Growth Strategy 2Obio Pharmaceutical Announces Product Growth Strategy 3Zogenix Reports FDA Provides New PDUFA Date for Sumavel(TM) DosePro(TM) 2
(Date:2/13/2015)... 2015 ACT Genomics Co., Ltd., a ... transform cancer genomic information into precision diagnosis and ... raised US$ 8 million in the its first private ... Taipei, Taiwan , ACT Genomics has developed ... aim to implement next generation sequencing (NGS) and ...
(Date:2/12/2015)... Conn. , Feb. 12, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62/113114 for DISTRIBUTED ... DEVICES. The patent further establishes NXT-ID,s position ... its intellectual property portfolio the ability for multiple devices ...
(Date:2/10/2015)... Mass., Feb. 10, 2015  Alere Inc. (NYSE: ... its financial results for the quarter ended December ... Officer and President of Alere said, "We made ... Alere as the global leader in rapid diagnostics ... the Alere Health divestiture in early January enabled ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33
... dead organisms could serve as a relatively fast, simple and ... University of Chicago,s Susan Kidwell explains how measuring the degree ... in the Oct. 26 early online edition of the Proceedings ... in many different ways, but the effects of our actions ...
... has been brought back to life in stunning 3D ... In a paper published in the latest issue of ... Ghent University in Belgium report on the use of ... (VHR-CT) to digitally dissect tiny fossils and reveal the ...
... latest American Chemical Society (ACS) News Service Weekly,press ... journals and Chemical & Engineering News. With more ... society. Please,cite the individual journal, or the American ... ARTICLE #1 FOR IMMEDIATE RELEASE , , "Microplastics" ...
Cached Biology News:Dead clams tell many tales 2Dead clams tell many tales 3Dead clams tell many tales 4Scientist brings 50 million year old spider 'back to life' 2American Chemical Society's Weekly PressPac -- Oct. 24, 2007 2American Chemical Society's Weekly PressPac -- Oct. 24, 2007 3American Chemical Society's Weekly PressPac -- Oct. 24, 2007 4American Chemical Society's Weekly PressPac -- Oct. 24, 2007 5American Chemical Society's Weekly PressPac -- Oct. 24, 2007 6American Chemical Society's Weekly PressPac -- Oct. 24, 2007 7American Chemical Society's Weekly PressPac -- Oct. 24, 2007 8
...
... Staining Kit, Protein, 1. Based on ... (1), the kit gives essentially colorless ... Staining Kit, Protein provides convenient, reproducible ... polyacrylamide gels in less than two ...
Mouse monoclonal [IFR0104] to Salmonella enteriditis ( Abpromise for all tested applications)....
Cyno macaque plasma and serum - various quantities available...
Biology Products: